Brazil caps tirzepatide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The Ledger in 2025
Page 6 of 10 of this archive, newest first.
The Netherlands declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Argentina caps exenatide prescribing to 8 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
Two-thirds back: the extension nobody expected to be the headline
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
Germany declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
How a claim degrades between the bench and the listing
Every step between the laboratory report and the product page removes information, and the badge is the last step.
Japan declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The dose that got you here and the dose that keeps you here
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Germany caps dulaglutide prescribing to 6 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Ireland declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Italy declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The named comparison we promised two years ago
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
From vial to bench: what is recorded and what is assumed
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
Poland caps semaglutide prescribing to 20 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
How a claim degrades between the bench and the listing
Every step between the laboratory report and the product page removes information, and the badge is the last step.
The lead-in, the randomisation, and the year that followed
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
Mexico declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The shortage years, and what they taught about interruption
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
Sweden declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.